150 related articles for article (PubMed ID: 28029522)
1. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain.
Sabater-Molina M; Saura D; García-Molina Sáez E; González-Carrillo J; Polo L; Pérez-Sánchez I; Olmo MDC; Oliva-Sandoval MJ; Barriales-Villa R; Carbonell P; Pascual-Figal D; Gimeno JR
Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):105-114. PubMed ID: 28029522
[TBL] [Abstract][Full Text] [Related]
2. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.
Méndez I; Fernández AI; Espinosa MÁ; Cuenca S; Lorca R; Rodríguez JF; Tamargo M; García-Montero M; Gómez C; Vilches S; Vázquez N; Álvarez R; Medrano C; Yotti R; Fernández-Avilés F; Bermejo J
Open Heart; 2021 Sep; 8(2):. PubMed ID: 34588271
[TBL] [Abstract][Full Text] [Related]
3. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.
Waldmüller S; Sakthivel S; Saadi AV; Selignow C; Rakesh PG; Golubenko M; Joseph PK; Padmakumar R; Richard P; Schwartz K; Tharakan JM; Rajamanickam C; Vosberg HP
J Mol Cell Cardiol; 2003 Jun; 35(6):623-36. PubMed ID: 12788380
[TBL] [Abstract][Full Text] [Related]
4. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
[TBL] [Abstract][Full Text] [Related]
5. Insights Into Hypertrophic Cardiomyopathy Evaluation Through Follow-up of a Founder Pathogenic Variant.
Lorca R; Gómez J; Martín M; Cabanillas R; Calvo J; León V; Pascual I; Morís C; Coto E; R Reguero JJ
Rev Esp Cardiol (Engl Ed); 2019 Feb; 72(2):138-144. PubMed ID: 29631964
[TBL] [Abstract][Full Text] [Related]
6. Hypertrophic cardiomyopathy in myosin-binding protein C (
Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
[TBL] [Abstract][Full Text] [Related]
7. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene.
Ehlermann P; Weichenhan D; Zehelein J; Steen H; Pribe R; Zeller R; Lehrke S; Zugck C; Ivandic BT; Katus HA
BMC Med Genet; 2008 Oct; 9():95. PubMed ID: 18957093
[TBL] [Abstract][Full Text] [Related]
8. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.
Hodatsu A; Konno T; Hayashi K; Funada A; Fujita T; Nagata Y; Fujino N; Kawashiri MA; Yamagishi M
Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1594-604. PubMed ID: 25281569
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy.
Velicki L; Jakovljevic DG; Preveden A; Golubovic M; Bjelobrk M; Ilic A; Stojsic S; Barlocco F; Tafelmeier M; Okwose N; Tesic M; Brennan P; Popovic D; Ristic A; MacGowan GA; Filipovic N; Maier LS; Olivotto I
BMC Cardiovasc Disord; 2020 Dec; 20(1):516. PubMed ID: 33297970
[TBL] [Abstract][Full Text] [Related]
11. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3.
Oliva-Sandoval MJ; Ruiz-Espejo F; Monserrat L; Hermida-Prieto M; Sabater M; García-Molina E; Ortiz M; Rodríguez-García MI; Núñez L; Gimeno JR; Castro-Beiras A; Valdés M
Heart; 2010 Dec; 96(24):1980-4. PubMed ID: 21088121
[TBL] [Abstract][Full Text] [Related]
12. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
[TBL] [Abstract][Full Text] [Related]
13. [The genotype-phenotype correlation of MYH7 gene G15391A mutation and MYBPC3 gene G12101A mutation in familial hypertrophic cardiomyopathy].
WANG H; ZOU YB; WANG JZ; SONG L; SUN K; SONG XD; WANG XJ; ZHANG CN; HUI RT
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Dec; 36(12):1059-62. PubMed ID: 19134269
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
[TBL] [Abstract][Full Text] [Related]
15. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
[TBL] [Abstract][Full Text] [Related]
16. [Familiar hypertrophic cardiomyopathy caused by a IVS15-1G > A mutation in cardiac myosin-binding protein C gene].
Zou YB; Wang JZ; Wu GR; Song L; Wang SX; Yu H; Zhang Q; Wang H; Hui RT
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Aug; 34(8):699-702. PubMed ID: 17081393
[TBL] [Abstract][Full Text] [Related]
17. A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
Teirlinck CH; Senni F; Malti RE; Majoor-Krakauer D; Fellmann F; Millat G; André-Fouët X; Pernot F; Stumpf M; Boutarin J; Bouvagnet P
BMC Med Genet; 2012 Nov; 13():105. PubMed ID: 23140321
[TBL] [Abstract][Full Text] [Related]
18. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
[TBL] [Abstract][Full Text] [Related]
20. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
